Clinical Trial Update: Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer [Phase 1]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 1 study evaluating gemcitabine with an antiangiogenic peptide vaccine in pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• antiangiogenic peptide vaccine therapy

Snippet

Sponsor: Wakayama Medical University | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED